Sinha, D.; Moseley, P.; Lu, X.; Wright, Q.; Gabrielli, B.; Frazer, I.H.; Cruz, J.L.G.
Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. Cancers 2022, 14, 6150.
https://doi.org/10.3390/cancers14246150
AMA Style
Sinha D, Moseley P, Lu X, Wright Q, Gabrielli B, Frazer IH, Cruz JLG.
Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. Cancers. 2022; 14(24):6150.
https://doi.org/10.3390/cancers14246150
Chicago/Turabian Style
Sinha, Debottam, Philip Moseley, Xuehan Lu, Quentin Wright, Brian Gabrielli, Ian H. Frazer, and Jazmina L. G. Cruz.
2022. "Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade" Cancers 14, no. 24: 6150.
https://doi.org/10.3390/cancers14246150
APA Style
Sinha, D., Moseley, P., Lu, X., Wright, Q., Gabrielli, B., Frazer, I. H., & Cruz, J. L. G.
(2022). Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. Cancers, 14(24), 6150.
https://doi.org/10.3390/cancers14246150